18F-DOPA PET/CT in brain tumors: impact on multidisciplinary brain tumor board decisions

PurposeThis study aimed to assess the therapeutic impact and diagnostic accuracy of 18F-DOPA PET/CT in patients with glioblastoma or brain metastases.MethodsPatients with histologically proven glioblastoma or brain metastases were prospectively included in this monocentric clinical trial (IMOTEP). Patients were included either due to a clinical suspicion of relapse or to assess residual tumor infiltration after treatment. Multimodality brain MRI and 18F-DOPA PET were performed. Patients’ data were discussed during a Multidisciplinary Neuro-oncology Tumor Board (MNTB) meeting. The discussion was first based on clinical and MRI data, and an initial diagnosis and treatment plan were proposed. Secondly, a new discussion was conducted based on the overall imaging results, including 18F-DOPA PET. A second diagnosis and therapeutic plan were proposed. A retrospective and definitive diagnosis was obtained after a 3-month follow-up and considered as the reference standard.ResultsOne hundred six cases were prospectively investigated by the MNTB. All patients with brain metastases (N = 41) had a clinical suspicion of recurrence. The addition of 18F-DOPA PET data changed the diagnosis and treatment plan in 39.0% and 17.1% of patients’ cases, respectively. Concerning patients with a suspicion of recurrent glioblastoma (N = 12), the implementation of 18F-DOPA PET changed the diagnosis and treatment plan in 33.3% of cases. In patients evaluated to assess residual glioblastoma infiltration after treatment (N = 53), 18F-DOPA PET data had a lower impact with only 5.7% (3/53) of diagnostic changes and 3.8% (2/53) of therapeutic plan changes. The definitive reference diagnosis was available in 98/106 patients. For patients with tumor recurrence suspicion, the adjunction of 18F-DOPA PET increased the Younden’s index from 0.44 to 0.53 in brain metastases and from 0.2 to 1.0 in glioblastoma, reflecting an increase in diagnostic accuracy.Conclusion18F-DOPA PET has a significant impact on the management of patients with a suspicion of brain tumor recurrence, either glioblastoma or brain metastases, but a low impact when used to evaluate the residual glioblastoma infiltration after a first-line radio-chemotherapy or second-line bevacizumab.

[1]  D. Taïeb,et al.  Role of 18F‐FDOPA PET/CT imaging in endocrinology , 2014, Clinical endocrinology.

[2]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[3]  C. Belka,et al.  [18F]Fluoroethyltyrosine–Positron Emission Tomography-Based Therapy Monitoring after Stereotactic Iodine-125 Brachytherapy in Patients with Recurrent High-Grade Glioma , 2013, Molecular imaging.

[4]  J. Carrasquillo,et al.  The Effects of Carbidopa on Uptake of 6-18F-Fluoro-l-DOPA in PET of Pheochromocytoma and Extraadrenal Abdominal Paraganglioma , 2007, Journal of Nuclear Medicine.

[5]  D. Schiff,et al.  Cerebral metastases—a therapeutic update , 2006, Nature Clinical Practice Neurology.

[6]  Wei Chen,et al.  Advances in evaluation of primary brain tumors. , 2008, Seminars in nuclear medicine.

[7]  G. Fink,et al.  Assessment of Treatment Response in Patients with Glioblastoma Using O-(2-18F-Fluoroethyl)-l-Tyrosine PET in Comparison to MRI , 2012, The Journal of Nuclear Medicine.

[8]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Tracy T Batchelor,et al.  Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas , 2008, Current opinion in neurology.

[10]  J. Barrio,et al.  Blood-brain barrier and neuronal membrane transport of 6-[18F]fluoro-L-DOPA. , 2001, Biochemical pharmacology.

[11]  Jacques Darcourt,et al.  Study of LAT1 Expression in Brain Metastases: Towards a Better Understanding of the Results of Positron Emission Tomography Using Amino Acid Tracers , 2016, PloS one.

[12]  J. Shinoda,et al.  Comparison of 11C-Methionine, 11C-Choline, and 18F-Fluorodeoxyglucose-Positron Emission Tomography for Distinguishing Glioma Recurrence from Radiation Necrosis , 2013, Neurologia medico-chirurgica.

[13]  F. Calabria,et al.  Molecular imaging of brain tumors with 18F-DOPA PET and PET/CT , 2012, Nuclear medicine communications.

[14]  J. Sherman,et al.  Current trends in the surgical management and treatment of adult glioblastoma. , 2015, Annals of translational medicine.

[15]  Michael E. Phelps,et al.  18F-FDOPA PET for Differentiating Recurrent or Progressive Brain Metastatic Tumors from Late or Delayed Radiation Injury After Radiation Treatment , 2014, The Journal of Nuclear Medicine.

[16]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[17]  T. Batchelor,et al.  Imaging and response criteria in gliomas , 2010, Current opinion in oncology.

[18]  Gereon R. Fink,et al.  Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-l-tyrosine PET , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  Christian Woiciechowsky,et al.  Correlation of F-18-fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomas , 2008, Journal of Neuro-Oncology.

[20]  A. Bizzi,et al.  Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  Abhishek Kumar,et al.  Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent glioma , 2013, European Radiology.

[22]  W. Burchert,et al.  3-O-Methyl-6-[18F]fluoro-l-DOPA and its evaluation in brain tumour imaging , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  G. Fink,et al.  Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-l-tyrosine PET in comparison to MRI , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  B. Gulyás,et al.  Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas , 2006, Journal of the Neurological Sciences.

[25]  J. Sarkaria,et al.  The role of LAT1 in 18F-DOPA uptake in malignant gliomas , 2012, Journal of Neuro-Oncology.

[26]  Wei Chen,et al.  18F-FDOPA Kinetics in Brain Tumors , 2007, Journal of Nuclear Medicine.

[27]  J. Posner,et al.  Brain metastases: epidemiology and pathophysiology , 2005, Journal of Neuro-Oncology.

[28]  Gereon R Fink,et al.  Static and dynamic 18F–FET PET for the characterization of gliomas defined by IDH and 1p/19q status , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  Jill S Barnholtz-Sloan,et al.  Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  T. Aigner,et al.  6-18F-L-DOPA imaging of the dopamine neostriatal system in normal and clinically normal MPTP-treated rhesus monkeys , 2004, Experimental Brain Research.

[31]  G. Reifenberger,et al.  EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. , 2014, The Lancet. Oncology.

[32]  Eric Guedj,et al.  18F-DOPA, a clinically available PET tracer to study brain inflammation? , 2014, Clinical nuclear medicine.

[33]  T. Nihashi,et al.  Diagnostic Accuracy of PET for Recurrent Glioma Diagnosis: A Meta-Analysis , 2013, American Journal of Neuroradiology.

[34]  Wei Chen,et al.  18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  Wei Chen.  Clinical Applications of PET in Brain Tumors* , 2007, Journal of Nuclear Medicine.

[36]  Wei Chen,et al.  18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. , 2009, European journal of radiology.

[37]  Ian Law,et al.  Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. , 2016, Neuro-oncology.

[38]  Francesco Scopinaro,et al.  Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[39]  R. Fimmers,et al.  Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET , 2015, Clinical Cancer Research.

[40]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[41]  N. Albert,et al.  Early static 18F-FET-PET scans have a higher accuracy for glioma grading than the standard 20–40 min scans , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[42]  M. Frosch,et al.  Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Ian Law,et al.  The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy , 2016, NeuroImage: Clinical.

[44]  T. Cloughesy,et al.  Impact of 3,4-Dihydroxy-6-18F-Fluoro-l-Phenylalanine PET/CT on Managing Patients with Brain Tumors: The Referring Physician's Perspective , 2012, The Journal of Nuclear Medicine.

[45]  M. Wyss,et al.  Early metabolic responses in temozolomide treated low-grade glioma patients , 2009, Journal of Neuro-Oncology.

[46]  R. Blasberg,et al.  “Facilitated” Amino Acid Transport is Upregulated in Brain Tumors , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.